Clinical Trial Update: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of CRS-207 with epacadostat in platinum-resistant ovarian, fallopian, or peritoneal cancer has been terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Fallopian Tube Cancer
• Platinum-resistant Ovarian Cancer
• Platinum-resistant Peritoneal Cancer

Drugs mentioned

• CRS-207
• Epacadostat (epacadostat)

Snippet

Sponsor: Aduro Biotech, Inc. | Conditions: Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-04-04